Clinical trial · people
Setmelanotide: quality of life rose after 52 weeks in Bardet-Biedl
Checked against the paper Clinical trialPublished by PepVault
The takeaway
For people with Bardet-Biedl syndrome, this trial adds that a year on setmelanotide came with meaningful gains in self-reported quality of life, and in adults those gains moved with weight change.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2023
- Journal
- Orphanet J Rare Dis
What they tested
The team asked whether health-related quality of life changed in children and adults with Bardet-Biedl syndrome, a rare genetic disease tied to constant hunger and severe early obesity, after 1 year of setmelanotide.
How the study was done
In a phase 3 trial, people with Bardet-Biedl syndrome and obesity received setmelanotide for 52 weeks. This analysis described changes in 9 patients under 18 and 11 adults who filled in quality of life questionnaires at the start of active treatment and at 52 weeks, without a comparison group.

Model. Individual results vary.
What they found
In those under 18, the PedsQL score (a pediatric quality of life questionnaire, where a 4.4-point change counts as meaningful) rose by a mean of +11.2. All 4 young patients whose scores showed impairment at the start improved by a clinically meaningful amount. In adults, the IWQOL-Lite score (a questionnaire on how weight affects daily life, where a 7.7 to 12-point change counts as meaningful) rose by a mean of +12.0, and 62.5% of the 8 adults with impaired scores at the start improved meaningfully. Among adults, the IWQOL-Lite score was significantly linked to how much their weight shifted in percent terms (P = 0.0037) and to the shift in BMI, a weight-for-height measure (P = 0.0098).
What it doesn’t show
This was a small group, and the results are descriptive with no placebo comparison, so they cannot show how much of the change came from the drug itself. Scores were self-reported or caregiver-reported, and only patients with data at both time points were included.
The paper
Forsythe et al. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.